TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The drug will be manufactured at the group’s topical facility at Ahmedabad
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Innate to receive $5M milestone payment from AstraZeneca
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Subscribe To Our Newsletter & Stay Updated
